RBC Capital analyst Conor McNamara maintains $Thermo Fisher Scientific (TMO.US)$ with a buy rating, and adjusts the target price from $767 to $718.
According to TipRanks data, the analyst has a success rate of 35.4% and a total average return of -9.9% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Thermo Fisher Scientific (TMO.US)$'s main analysts recently are as follows:
Thermo Fisher's recent quarterly performance met expectations in a period where anticipation was high. The company demonstrated strong execution amid a challenging demand scenario within the tools sector, with uncertainty looming over the timing of demand resurgence.
While Thermo Fisher's third-quarter earnings call was more optimistic than its results, there remains a positive outlook on the stock. The Life Sciences Solutions segment continues to experience bioproduction momentum, and the Laboratory Products and Biopharma Services segment does not appear to be affected by a biotech slowdown.
Thermo Fisher's core growth has been observed to be on a consistent upward trajectory quarter-over-quarter, with projections suggesting a slight increase to approximately +2.5% in the fourth quarter. Expectations on the Street for a 5% core growth by 2025 appear to be solid and justifiable. The company's defensive profile and balance sheet flexibility remain favorable.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
加皇資本市場分析師Conor McNamara維持$賽默飛世爾 (TMO.US)$買入評級，並將目標價從767美元下調至718美元。
根據TipRanks數據顯示，該分析師近一年總勝率為35.4%，總平均回報率為-9.9%。
此外，綜合報道，$賽默飛世爾 (TMO.US)$近期主要分析師觀點如下：
Thermo Fisher最近的季度表現符合人們的期望，儘管在工具板塊的需求形勢嚴峻，不確定因素籠罩着需求復甦的時機，但公司展現出了強大的執行能力。
儘管Thermo Fisher第三季度的業績會比其結果更加樂觀，但對該股票仍然持有積極的展望。生命科學解決方案板塊持續經歷生物生產的勢頭，實驗室產品和生物製藥服務板塊似乎不受生物技術放緩的影響。
Thermo Fisher的核心增長已被觀察到按季度持續向上軌跡發展，預測顯示第四季度將略有增長，約爲+2.5%。2025年街頭對5%核心增長的預期似乎是穩固且合理的。公司的防禦性特點和資產負債表靈活性仍然有利。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
